CSB2: Council for Systems Biology in Boston

Merrimack Pharmaceuticals

Merrimack Pharmaceuticals, Inc. is a privately held, biopharmaceutical company aspiring to be the leading provider of integrated medicines. The Company is advancing a suite of engineered therapeutics integrated with molecular diagnostics designed to address significant medical needs in the treatment of cancer and inflammation. Merrimack’s integrated medicines (therapeutics paired with diagnostics) are developed out of our proprietary R&D platform, Network Biology, which integrates the technologies of engineering, biology, and computing to enable mechanism-based, model driven discovery and development of both therapeutics and diagnostics.

The Company’s clinical assets include MM-121, an anti-ErbB3 antagonist currently in Phase 2, MM-111, a novel, bi-specific antibody targeting ErbB2/3 in Phase 1/2, MM-398, nanoliposomal CPT-11 in Phase 2 as well as multiple pre-clinical and research programs. Merrimack operates as a fully integrated R&D organization backed by leading healthcare investors, an outstanding board, and experienced management. Merrimack is always searching for talented individuals to join our team who share our passion for improving medicine, our entrepreneurial values, and seek to make a difference.